TRIM25 in Septic Patients
Key facts
- Who runs it
- Ruijin Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 65 people, planned
- Started
- 10 Dec 2021
- Planned end
- 1 Jul 2026
- Type of study
- Observational
- Treatments tested
- Gene and Inflammatory Marker Analysis in Sepsis
- Record updated
- 6 January 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- 1. SOFA score >=2; 2. Aged 18-70 years male and female; 3. Hospitalization
Who cannot take part
- 1. Immune system disease, such as HIV; 2. Disease that possibly affect the function of immune system, such as tumor and chronic viral infection; 3. Patients that treated with massive cortical hormone (>200mg/d) or immunosuppressant; 4. Pregnant or lactation women
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Sepsis is a life-threatening condition caused by the body's overwhelming response to infection, which can lead to organ damage and failure. The goal of this observational study is to better understand the underlying biological changes that occur in patients with sepsis compared to those who do not have the condition.
Read full original descriptionShow less
We will collect peripheral blood samples from patients diagnosed with sepsis and from non-sepsis control participants. From these samples, we will isolate peripheral blood mononuclear cells (PBMCs) and serum.
We will then analyze these components to measure the activity of specific genes and the levels of key inflammatory factors (cytokines).
The information we gather will help researchers identify molecular and inflammatory markers associated with sepsis. This knowledge is crucial for developing new and more effective methods for diagnosing and treating this critical illness.
The group in the trial
- Non-sepsis patients
Sepsis patients
Treatment: Gene and Inflammatory Marker Analysis in Sepsis
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Expression of Trim25 in Peripheral Blood Mononuclear Cells of Patients With Sepsis and Non-sepsis and Its Relationship With the Prognosis of Patients With Sepsis
- Criteria questions
- Built from NCT07320638, who can take part
- Record updated
- 6 January 2026